CA
NZ
UK
AU
IND
US
● What is verifiable is a steady stream of activity: on 27 August 2026 Caris published a study in npj Precision Oncology indicating AI-guided therapy selection was associated with longer survival in pancreatic cancer patients, on 2 September it said it would present research …
Priced in fractions of a cent and valued at roughly a million dollars, China Dongsheng International, Inc (OTC: CDSG) is a classic sub-penny shell stock, and one whoseBusinessbears little resemblance to what its name suggests. Rather than a Chinese health-products enterprise, CDSG today is …
CDT Equity Inc (NASDAQ:CDT) is a company in the middle of reinventing itself, so much so that its name changed in 2026. Formerly Conduit Pharmaceuticals, the micro-cap has broadened well beyond its original drug-development roots, adding investments in areas as varied as peptides and …
● Black Diamond Therapeutics is a Cambridge, Massachusetts-based precision-oncology company.
ACybersecuritybreach has forced one of the largest names in medical devices to warn that it will miss its own financial targets. Boston Scientific Corporation (NYSE: BSX) disclosed that unauthorized network activity disruptedManufacturingand shipping across its global operations, and that the fallout will materially dent …
Affimed N.V. (OTC:AFMDQ) is a cautionary chapter in immuno-oncology. Once a Nasdaq-listed developer of innate-immunity cancer therapies with a well-followed pipeline, the company's shares have collapsed to a fraction of a cent and now change hands over the counter under a ticker carrying the …
AlumiFuel Power Corporation (OTC:AFPW) belongs to a quiet corner of the market where once-promising clean-energy stories went dark. The company built its pitch around hydrogen, generating gas and heat by reacting aluminum with water, but its most recent verifiable milestones date back roughly half …
Amarantus BioScience Holdings, Inc (OTC:AMBS) has spent years chasing ambitious ideas across neurology, diagnostics and regenerative medicine, yet its stock tells a starker story. AMBS now changes hands at a fraction of a cent, with aMarket Valuemeasured in the hundreds of dollars and no …
● For a profitable, cash-generating pharmaceutical company, share performance tends to track fundamentals and sector sentiment rather than binary news.
Anthera Pharmaceuticals (OTC:ANTH) belongs to a large graveyard of clinical-stage biotechs whose lead programs failed and whose shares dwindled to almost nothing. Once a Nasdaq-listed developer of treatments for autoimmune and rare diseases, Anthera has left virtually no fresh public footprint for years.
Please wait processing your request...